1. Jones R. Nonsteroidal anti-inflammatory drug prescribing: past, present, and future. Am J Med 2001;110(suppl 1A):4–7.
2. Leroux H. J Chim Med 1830;6:341.
3. Sneader W. The discovery of aspirin: a reappraisal. BMJ 2000;321 (7276):1591–1594.
4. Vieson K. Overview: Nonsteroidal antiinflammatory drugs. In: Clinical pharmacology. Vol. 2003. Gold Standard Multimedia, 2000.
5. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433–442.
6. Simon L, Lipman A, Jacox A, et al. Guideline for the management of arthritis pain in osteoarthritis, rheumatoid arthritis, and juvenile chronic arthritis. Glenview, IL: American Pain Society, 2002 (APS Clinical Practice Guidelines Series, No. 2).
7. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000; 43:1905–1915.
8. The management of persistent pain in older persons. J Am Geriatr Soc 2002;50(suppl):205–224.
9. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232–235.
10. Pash JM, Bailey JM. Inhibition by corticosteroids of epidermal growth factor-induced recovery of cyclooxygenase after aspirin inactivation. FASEB J 1988;2:2613–2618.
11. Sebaldt RJ, Sheller JR, Oates JA, et al. Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc Natl Acad Sci U S A 1990;87:6974–6978.
12. Masferrer JL, Zweifel BS, Seibert K, et al. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 1990;86:1375–1379.
13. Xie WL, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991;88:2692–2696.
14. Kujubu DA, Herschman HR. Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. J Biol Chem 1992;267:7991–7994.
15. O’Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci U S A 1992;89:4888–4892.
16. Toh H, Yokoyama C, Tanabe T, et al. Molecular evolution of cyclooxygenase and lipoxygenase. Prostaglandins 1992;44:291–315.
17. Morita I, Schindler M, Regier MK, et al. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem 1995;270:10902–10908.
18. Smith WL. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 1992;263(2 part 2):F181–F191.
19. Komhoff M, Grone HJ, Klein T, et al. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1997;272(4 part 2):F460–F468.
20. Harris RC, McKanna JA, Akai Y, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994;94:2504–2510.
21. Rocca B, Spain LM, Pure E, et al. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J Clin Invest 1999;103:1469–1477.
22. Smith CJ, Morrow JD, Roberts LJ 2nd, et al. Induction of prostaglandin endoperoxide synthase-1 (COX-1) in a human promonocytic cell line by treatment with the differentiating agent TPA. Adv Exp Med Biol 1997;400A:99–106.
23. Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995;2:637–643.
24. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975;56:624–632.
25. Wu KK. Biochemical pharmacology of nonsteroidal anti-inflammatory drugs. Biochem Pharmacol 1998;55:543–547.
26. Wu KK, Sanduja R, Tsai AL, et al. Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells. Proc Natl Acad Sci U S A 1991;88:2384–2387.
27. Weissmann G. Prostaglandins as modulators rather than mediators of inflammation. J Lipid Mediat 1993;6:275–286.
28. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994;265:956–959.
29. Gautam SC, Pindolia KR, Noth CJ, et al. Chemokine gene expression in bone marrow stromal cells: downregulation with sodium salicylate. Blood 1995;86:2541–2550.
30. Farivar RS, Brecher P. Salicylate is a transcriptional inhibitor of the inducible nitric oxide synthase in cultured cardiac fibroblasts. J Biol Chem 1996;271:31585–31592.
31. Schwenger P, Skolnik EY, Vilcek J. Inhibition of tumor necrosis factor-induced p42/p44 mitogen-activated protein kinase activation by sodium salicylate. J Biol Chem 1996;271:8089–8094.
32. Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999;5:1418–1423.
33. Lecomte M, Laneuville O, Ji C, et al. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem 1994;269:13207–13215.
34. Claria J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A 1995;92:9475–9479.
35. Serhan CN, Takano T, Maddox JF. Aspirin-triggered 15-epi-lipoxin A4 and stable analogs on lipoxin A4 are potent inhibitors of acute inflammation. Receptors and pathways. Adv Exp Med Biol 1999;447: 133–149.
36. Ito S, Okuda-Ashitaka E, Minami T. Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neurosci Res 2001;41:299–332.
37. Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A 1994;91:12013–12017.
38. Yamagata K, Andreasson KI, Kaufmann WE, et al. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993;11:371–386.
39. Breder CD, Smith WL, Raz A, et al. Distribution and characterization of cyclooxygenase immunoreactivity in the ovine brain. J Comp Neurol 1992;322:409–438.
40. Breder CD, Saper CB. Expression of inducible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharide. Brain Res 1996;713:64–69.
41. Beiche F, Scheuerer S, Brune K, et al. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 1996;390:165–169.
42. Beiche F, Klein T, Nusing R, et al. Localization of cyclooxygenase-2 and prostaglandin E2 receptor EP3 in the rat lumbar spinal cord. J Neuroimmunol 1998;89:26–34.
43. Chopra B, Giblett S, Little JG, et al. Cyclooxygenase-1 is a marker for a subpopulation of putative nociceptive neurons in rat dorsal root ganglia. Eur J Neurosci 2000;12:911–920.
44. Engblom D, Ek M, Hallbeck M, et al. Distribution of prostaglandin EP(3) and EP(4) receptor mRNA in the rat parabrachial nucleus. Neurosci Lett 2000;281:163–166.
45. Nakamura K, Kaneko T, Yamashita Y, et al. Immunohistochemical localization of prostaglandin EP3 receptor in the rat nervous system. J Comp Neurol 2000;421:543–569.
46. Ek M, Arias C, Sawchenko P, et al. Distribution of the EP3 prostaglandin E(2) receptor subtype in the rat brain: relationship to sites of interleukin-1-induced cellular responsiveness. J Comp Neurol 2000; 428:5–20.
47. Coceani F, Akarsu ES. Prostaglandin E2 in the pathogenesis of fever. An update. Ann NY Acad Sci 1998;856:76–82.
48. Ushikubi F, Segi E, Sugimoto Y, et al. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 1998;395:281–284.
49. Li S, Wang Y, Matsumura K, et al. The febrile response to lipopolysaccharide is blocked in cyclooxygenase-2(2/2), but not in cyclooxygenase-1(2/2) mice. Brain Res 1999;825:86–94.
50. Schwartz JI, Chan CC, Mukhopadhyay S, et al. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. Clin Pharmacol Ther 1999;65:653–660.
51. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/ antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002;99:13926–13931.
52. Awtry EH, Loscalzo J. Aspirin. Circulation 2000;101:1206–1218.
53. Owen PR. Prostaglandin synthetase inhibitors in the treatment of primary dysmenorrhea. Outcome trials reviewed. Am J Obstet Gynecol 1984;148:96–103.
54. Morrison BW, Daniels SE, Kotey P, et al. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol 1999;94:504–508.
55. Daniels SE, Talwalker S, Torri S, et al. Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea. Obstet Gynecol 2002;100:350–358.
56. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003;24:96–102.
57. Aisen PS. Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer’s disease. J Pain Symptom Manage 2002;23(suppl):35–40.
58. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983;24:83–87.
59. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946–1952.
60. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609–614.
61. Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241–246.
62. Greenberg ER, Baron JA, Freeman DH Jr, et al. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst 1993;85:912–916.
63. Peleg, II, Maibach HT, Brown SH, et al. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994;154:394–399.
64. Thun MJ, Namboodiri MM, Calle EE, et al. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322–1327.
65. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593–1596.
66. Collet JP, Sharpe C, Belzile E, et al. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer 1999;81:62–68.
67. Logan RF, Little J, Hawtin PG, et al. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ 1993;307:285–289.
68. Muscat JE, Stellman SD, Wynder EL. Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer 1994;74:1847–1854.
69. Peleg, II, Lubin MF, Cotsonis GA, et al. Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig Dis Sci 1996;41:1319–1326.
70. Reeves MJ, Newcomb PA, Trentham-Dietz A, et al. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 1996;5:955–960.
71. Smalley W, Ray WA, Daugherty J, et al. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 1999;159:161–166.
72. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883–890.
73. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891–899.
74. Imperiale TF. Aspirin and the prevention of colorectal cancer. N Engl J Med 2003;348:879–880.
75. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 1995;21:195–218.
76. Breitner JC. Inflammatory processes and antiinflammatory drugs in Alzheimer’s disease: a current appraisal. Neurobiol Aging 1996;17: 789–794.
77. in t’ Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 2001; 345:1515–1521.
78. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289:2819–2826.
79. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888–1899.
80. Tamblyn R, Berkson L, Dauphinee WD, et al. Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann Intern Med 1997;127:429–438.
81. Douthwaite AH, Lintott GAM. Gastroscopic observation of effect of aspirin and certain other substances on stomach. Lancet 1938;2:1222–1225.
82. Bjorkman D. Commentary: Gastrointestinal safety of coxibs and outcomes studies: what’s the verdict? J Pain Symptom Manage 2002;23 (suppl):11–14.
83. Sun DC, Roth SH, Mitchell CS, et al. Upper gastrointestinal disease in rheumatoid arthritis. Am J Dig Dis 1974;19:405–410.
84. Levy M. Aspirin use in patients with major upper gastrointestinal bleeding and peptic-ulcer disease. A report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. N Engl J Med 1974;290:1158–1162.
85. Silvoso GR, Ivey KJ, Butt JH, et al. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med 1979;91:517–520.
86. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999;26(suppl 56):18–24.
87. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123:241–249.
88. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827–830.
89. Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 1989;86:449–458.
90. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987;28: 527–532.
91. Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996;156:1530–1536.
92. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/ perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160:2093–2099.
93. MacDonald TM. Epidemiology and pharmacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity. Rheumatology (Oxford) 2000;39(suppl 2):13–20; discussion 57–59.
94. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002: CD002296.
95. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967–973.
96. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343:1520–1528.
97. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247–1255.
98. Laine L. Review article: The effect of Helicobacter pylori infection on nonsteroidal anti-inflammatory drug-induced upper gastrointestinal tract injury. Aliment Pharmacol Ther 2002;16(suppl 1):34–39.
99. Laine L, Cominelli F, Sloane R, et al. Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double-blind trial. Aliment Pharmacol Ther 1995;9:127–135.
100. Thillainayagam AV, Tabaqchali S, Warrington SJ, et al. Interrelationships between Helicobacter pylori infection, nonsteroidal antiinflammatory drugs and gastroduodenal disease. A prospective study in healthy volunteers. Dig Dis Sci 1994;39:1085–1089.
101. Kim JG, Graham DY. Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy. The Misoprostol Study Group. Am J Gastroenterol 1994;89:203–207.
102. Goggin PM, Collins DA, Jazrawi RP, et al. Prevalence of Helicobacter pylori infection and its effect on symptoms and non-steroidal anti-inflammatory drug induced gastrointestinal damage in patients with rheumatoid arthritis. Gut 1993;34:1677–1680.
103. Lanza FL, Evans DG, Graham DY. Effect of Helicobacter pylori infection on the severity of gastroduodenal mucosal injury after the acute administration of naproxen or aspirin to normal volunteers. Am J Gastroenterol 1991;86:735–737.
104. Bannwarth B, Dorval E, Caekaert A, et al. Influence of Helicobacter pylori eradication therapy on the occurrence of gastrointestinal events in patients treated with conventional nonsteroidal antiinflammatory drugs combined with omeprazole. J Rheumatol 2002;29: 1975–1980.
105. Taha AS, Dahill S, Morran C, et al. Neutrophils, Helicobacter pylori, and nonsteroidal anti-inflammatory drug ulcers. Gastroenterology 1999;116:254–258.
106. Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997;350:975–979.
107. Labenz J, Blum AL, Bolten WW, et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut 2002;51:329–335.
108. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998;338:719–726.
109. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998;338: 727–734.
110. Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998;352:1016–1021.
111. Agrawal NM, Campbell DR, Safdi MA, et al. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med 2000;160:1455–1461.
112. Chan FK, Sung JJ, Suen R, et al. Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study. Aliment Pharmacol Ther 1998;12:1201–1205.
113. Talley NJ, Zinsmeister AR, Schleck CD, et al. Smoking, alcohol, and analgesics in dyspepsia and among dyspepsia subgroups: lack of an association in a community. Gut 1994;35:619–624.
114. Talley NJ, Evans JM, Fleming KC, et al. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci 1995;40: 1345–1350.
115. Watson DJ, Harper SE, Zhao PL, et al. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000;160:2998–3003.
116. Larkai EN, Smith JL, Lidsky MD, et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82: 1153–1158.
117. Pounder R. Silent peptic ulceration: deadly silence or golden silence? Gastroenterology 1989;96(part 2; suppl):626–631.
118. Bijlsma JW. Treatment of NSAID-induced gastrointestinal lesions with cimetidine: an international multicentre collaborative study. Aliment Pharmacol Ther 1988;2(suppl 1):85–95.
119. Lanza FL, Aspinall RL, Swabb EA, et al. Double-blind, placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum. Gastroenterology 1988;95:289–294.
120. Saunders JH, Oliver RJ, Higson DL. Dyspepsia: incidence of a non-ulcer disease in a controlled trial of ranitidine in general practice. BMJ (Clin Res) 1986;292:665–668.
121. Van Groenendael JH, Markusse HM, Dijkmans BA, et al. The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 1996;15:450–456.
122. Matsuhashi N, Yamada A, Hiraishi M, et al. Multiple strictures of the small intestine after long-term nonsteroidal anti-inflammatory drug therapy. Am J Gastroenterol 1992;87:1183–1186.
123. Hershfield NB. Endoscopic demonstration of non-steroidal anti-inflammatory drug-induced small intestinal strictures. Gastrointest Endosc 1992;38:388–390.
124. Saw KC, Quick CR, Higgins AF. Ileocaecal perforation and bleeding—are non-steroidal anti-inflammatory drugs (NSAIDs) responsible? [comment]. J R Soc Med 1990;83:114–115.
125. Lang J, Price AB, Levi AJ, et al. Diaphragm disease: pathology of disease of the small intestine induced by non-steroidal anti-inflammatory drugs. J Clin Pathol 1988;41:516–526.
126. Bjarnason I, Price AB, Zanelli G, et al. Clinicopathological features of nonsteroidal antiinflammatory drug-induced small intestinal strictures. Gastroenterology 1988;94:1070–1074.
127. Sukumar L. Recurrent small bowel obstruction associated with piroxicam. Br J Surg 1987;74:186.
128. Fang WF, Broughton A, Jacobson ED. Indomethacin-induced intestinal inflammation. Am J Dig Dis 1977;22:749–760.
129. Sturges HF, Krone CL. Ulceration and stricture of the jejunum in a patient on long-term indomethacin therapy. Am J Gastroenterol 1973;59:162–169.
130. Bjorkman D. Nonsteroidal anti-inflammatory drug-associated toxicity of the liver, lower gastrointestinal tract, and esophagus. Am J Med 1998;105(suppl):17–21.
131. Kessler WF, Shires GT 3rd, Fahey TJ 3rd. Surgical complications of nonsteroidal antiinflammatory drug-induced small bowel ulceration. J Am Coll Surg 1997;185:250–254.
132. Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003;124:288–292.
133. Tolman KG. Hepatotoxicity of non-narcotic analgesics. Am J Med 1998;105(suppl):13–19.
134. Fry SW, Seeff LB. Hepatotoxicity of analgesics and anti-inflammatory agents. Gastroenterol Clin North Am 1995;24:875–905.
135. Carson JL, Strom BL, Duff A, et al. Safety of nonsteroidal anti-inflammatory drugs with respect to acute liver disease. Arch Intern Med 1993;153:1331–1336.
136. Tarazi EM, Harter JG, Zimmerman HJ, et al. Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration. Gastroenterology 1993;104:569–574.
137. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991;31:588–598.
138. Harris RC Jr. Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol 2002;89:10D–17D.
139. Henrich WL, Agodoa LE, Barrett B, et al. Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis 1996;27: 162–165.
140. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999; 106(suppl):13–24.
141. Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000;133: 1–9.
142. Smith WL, Bell TG. Immunohistochemical localization of the prostaglandin-forming cyclooxygenase in renal cortex. Am J Physiol 1978;235:F451–F457.
143. Yang T, Singh I, Pham H, et al. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol 1998; 274:F481–F489.
144. Ichihara A, Imig JD, Inscho EW, et al. Cyclooxygenase-2 participates in tubular flow-dependent afferent arteriolar tone: interaction with neuronal NOS. Am J Physiol 1998;275:F605–F612.
145. Harding P, Sigmon DH, Alfie ME, et al. Cyclooxygenase-2 mediates increased renal renin content induced by low-sodium diet. Hypertension 1997;29:297–302.
146. Komhoff M, Jeck ND, Seyberth HW, et al. Cyclooxygenase-2 expression is associated with the renal macula densa of patients with Bartter-like syndrome. Kidney Int 2000;58:2420–2424.
147. Whelton A, Maurath CJ, Verburg KM, et al. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 2000;7:159–175.
148. Gertz BJ, Krupa D, Bolognese JA, et al. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. Curr Med Res Opin 2002;18:82–91.
149. Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med 1999;107(suppl):65–70; discussion 70–71.
150. Whelton A. Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics. Am J Ther 2000;7:63–74.
151. Schwartz JI, Vandormael K, Malice MP, et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 2002;72: 50–61.
152. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289:735–741.
153. Epstein M. Renal prostaglandins and the control of renal function in liver disease. Am J Med 1986;80:46–55.
154. Oates JA, FitzGerald GA, Branch RA, et al. Clinical implications of prostaglandin and thromboxane A2 formation (1). N Engl J Med 1988;319:689–698.
155. Walshe JJ, Venuto RC. Acute oliguric renal failure induced by indomethacin: possible mechanism. Ann Intern Med 1979;91: 47–49.
156. Arisz L, Donker AJ, Brentjens JR, et al. The effect of indomethacin on proteinuria and kidney function in the nephrotic syndrome. Acta Med Scand 1976;199:121–125.
157. Kleinknecht C, Broyer M, Gubler MC, et al. Irreversible renal failure after indomethacin in steroid-resistant nephrosis. N Engl J Med 1980;302:691.
158. Blackshear JL, Napier JS, Davidman M, et al. Renal complications of nonsteroidal antiinflammatory drugs: identification and monitoring of those at risk. Semin Arthritis Rheum 1985;14: 163–175.
159. Favre L, Glasson P, Vallotton MB. Reversible acute renal failure from combined triamterene and indomethacin: a study in healthy subjects. Ann Intern Med 1982;96:317–320.
160. McCarthy JT, Torres VE, Romero JC, et al. Acute intrinsic renal failure induced by indomethacin: role of prostaglandin synthetase inhibition. Mayo Clin Proc 1982;57:289–296.
161. Henry D, Page J, Whyte I, et al. Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study. Br J Clin Pharmacol 1997;44:85–90.
162. Hay E, Derazon H, Bukish N, et al. Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet. J Emerg Med 2002;22:349–352.
163. Jolobe OM. Nephrotoxicity in the elderly due to co-prescription of ACE inhibitors and NSAIDs. J R Soc Med 2001;94:657–658.
164. Akbarpour F, Afrasiabi A, Vaziri ND. Severe hyperkalemia caused by indomethacin and potassium supplementation. South Med J 1985; 78:756–767.
165. Mor R, Pitlik S, Rosenfeld JB. Indomethacin- and moduretic-induced hyperkalemia. Isr J Med Sci 1983;19:535–537.
166. Galler M, Folkert VW, Schlondorff D. Reversible acute renal insufficiency and hyperkalemia following indomethacin therapy. JAMA 1981;246:154–155.
167. Nicholls MG, Espiner EA. Indomethacin-induced azotaemia and hyperkalaemia: a case study. N Z Med J 1981;94:377–379.
168. Findling JW, Beckstrom D, Rawsthorne L, et al. Indomethacin-induced hyperkalemia in three patients with gouty arthritis. JAMA 1980;244:1127–1128.
169. Paladini G, Tonazzi C. Indomethacin-induced hyperkalemia and renal failure in multiple myeloma. Acta Haematol 1982;68:256–260.
170. Kelley M, Bastani B. Ketorolac-induced acute renal failure and hyperkalemia. Clin Nephrol 1995;44:276–277.
171. Patel P, Mandal B, Greenway MW. Hyperkalaemic quadriparesis secondary to chronic diclofenac treatment. Postgrad Med J 2001;77: 50–51.
172. Apostolou T, Sotsiou F, Yfanti G, et al. Acute renal failure induced by nimesulide in a patient suffering from temporal arteritis. Nephrol Dial Transplant 1997;12:1493–1496.
173. Pal B, Hutchinson A, Bhattacharya A, et al. Cardiac arrest due to severe hyperkalaemia in patient taking nabumetone and low salt diet. BMJ 1995;311:1486–1487.
174. Abraham PA, Keane WF. Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. Am J Nephrol 1984; 4:1–6.
175. Bender WL, Whelton A, Beschorner WE, et al. Interstitial nephritis, proteinuria, and renal failure caused by nonsteroidal anti-inflammatory drugs. Immunologic characterization of the inflammatory infiltrate. Am J Med 1984;76:1006–1012.
176. Levin ML. Patterns of tubulo-interstitial damage associated with nonsteroidal antiinflammatory drugs. Semin Nephrol 1988;8:55–61.
177. Husserl FE, Lange RK, Kantrow CM Jr. Renal papillary necrosis and pyelonephritis accompanying fenoprofen therapy. JAMA 1979;242: 1896–1898.
178. Shah GM, Muhalwas KK, Winer RL. Renal papillary necrosis due to ibuprofen. Arthritis Rheum 1981;24:1208–1210.
179. Morales A, Steyn J. Papillary necrosis following phenylbutazone ingestion. Arch Surg 1971;103:420–421.
180. Murray TG, Goldberg M. Analgesic-associated nephropathy in the U.S.A.: epidemiologic, clinical and pathogenetic features. Kidney Int 1978;13:64–71.
181. Nanra RS, Stuart-Taylor J, de Leon AH, et al. Analgesic nephropathy: etiology, clinical syndrome, and clinicopathologic correlations in Australia. Kidney Int 1978;13:79–92.
182. De Broe ME, Elseviers MM. Analgesic nephropathy. N Engl J Med 1998;338:446–452.
183. Elseviers MM, De Broe ME. A long-term prospective controlled study of analgesic abuse in Belgium. Kidney Int 1995;48:1912–1919.
184. Elseviers MM, De Schepper A, Corthouts R, et al. High diagnostic performance of CT scan for analgesic nephropathy in patients with incipient to severe renal failure. Kidney Int 1995;48:1316–1323.
185. Elseviers MM, Waller I, Nenoy D, et al. Evaluation of diagnostic criteria for analgesic nephropathy in patients with end-stage renal failure: results of the ANNE study. Analgesic Nephropathy Network of Europe. Nephrol Dial Transplant 1995;10:808–814.
186. Piper JM, Tonascia J, Matanoski GM. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med 1985; 313:292–295.
187. Blohme I, Johansson S. Renal pelvic neoplasms and atypical urothelium in patients with end-stage analgesic nephropathy. Kidney Int 1981;20:671–675.
188. McCredie M, Stewart JH, Carter JJ, et al. Phenacetin and papillary necrosis: independent risk factors for renal pelvic cancer. Kidney Int 1986;30:81–84.
189. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121:289–300.
190. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477–484.
191. Komers R, Anderson S, Epstein M. Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors. Am J Kidney Dis 2001;38: 1145–1157.
192. Vioxx. Prescribing information, Merck, Inc.
193. Johnson AG, Simons LA, Simons J, et al. Non-steroidal anti-inflammatory drugs and hypertension in the elderly: a community-based cross-sectional study. Br J Clin Pharmacol 1993;35:455–459.
194. Gurwitz JH, Avorn J, Bohn RL, et al. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA 1994;272:781–786.
195. Schooley RT, Wagley PF, Lietman PS. Edema associated with ibuprofen therapy. JAMA 1977;237:1716–1717.
196. Tashima CK, Rose M. Letter: Pulmonary edema and salicylates. Ann Intern Med 1974;81:274–275.
197. Nevins M, Berque S, Corwin N, et al. Phenylbutazone and pulmonary oedema. Lancet 1969;2:1358.
198. Van den Ouweland FA, Gribnau FW, Meyboom RH. Congestive heart failure due to nonsteroidal anti-inflammatory drugs in the elderly. Age Ageing 1988;17:8–16.
199. Feenstra J, Grobbee DE, Mosterd A, et al. Adverse cardiovascular effects of NSAIDs in patients with congestive heart failure. Drug Saf 1997;17:166–180.
200. Heerdink ER, Leufkens HG, Herings RM, et al. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998;158:1108–1112.
201. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000;160:777–784.
202. Feenstra J, Heerdink ER, Grobbee DE, et al. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Arch Intern Med 2002;162:265–270.
203. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86.
204. Baigent C, Patrono C. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. Arthritis Rheum 2003;48: 12–20.
205. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104:2280–2288.
206. Van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000;40:1109–1120.
207. Watson DJ, Rhodes T, Cai B, et al. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002;162:1105–1110.
208. FitzGerald GA, Cheng Y, Austin S. COX-2 inhibitors and the cardiovascular system. Clin Exp Rheumatol 2001;19(suppl 25): 31–36.
209. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002;296:539–541.
210. Namazy JA, Simon RA. Sensitivity to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002;89:542–550; quiz 550, 605.
211. Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol 2001;87:177–180.
212. McDonald JR, Mathison DA, Stevenson DD. Aspirin intolerance in asthma. Detection by oral challenge. J Allergy Clin Immunol 1972;50:198–207.
213. Giraldo B, Blumenthal MN, Spink WW. Aspirin intolerance and asthma. A clinical and immunological study. Ann Intern Med 1969; 71:479–496.
214. Arm JP, O’Hickey SP, Spur BW, et al. Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma. Am Rev Respir Dis 1989;140:148–153.
215. Christie PE, Tagari P, Ford-Hutchinson AW, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991;143:1025–1029.
216. Mastalerz L, Gawlewicz-Mroczka A, Nizankowska E, et al. Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma. Clin Exp Allergy 2002;32:1360–1365.
217. Dahlen SE, Malmstrom K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:9–14.
218. Stevenson DD. Aspirin desensitization in patients with AERD. Clin Rev Allergy Immunol 2003;24:159–168.
219. Gyllfors P, Bochenek G, Overholt J, et al. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 2003;111:1116–1121.
220. Woessner KM, Simon RA, Stevenson DD. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum 2002;46: 2201–2206.
221. Martin-Garcia C, Hinojosa M, Berges P, et al. Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 2002;121:1812–1817.
222. Szczeklik A, Nizankowska E, Bochenek G, et al. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001; 31:219–225.
223. Marks F, Harrell K, Fischer R. Successful use of cyclooxygenase-2 inhibitor in a patient with aspirin-induced asthma. South Med J 2001; 94:256–257.
224. Moore-Robinson M, Warin RP. Effect of salicylates in urticaria. BMJ 1967;4:262–264.
225. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. NSAID-induced urticaria and angioedema: a reappraisal of its clinical management. Am J Clin Dermatol 2002;3:599–607.
226. Perez C, Sanchez-Borges M, Capriles E. Pretreatment with montelukast blocks NSAID-induced urticaria and angioedema. J Allergy Clin Immunol 2001;108:1060–1061.
227. Pacor ML, Di Lorenzo G, Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy 2001;31:1607–1614.
228. Asero R. Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. Ann Allergy Asthma Immunol 2000;85:156–157.
229. Quiralte J, Saenz de San Pedro B, Florido JJ. Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann Allergy Asthma Immunol 2002;89: 63–66.
230. Pacor ML, Di Lorenzo G, Biasi D, et al. Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. Clin Exp Allergy 2002;32: 397–400.
231. Nettis E, Di PR, Ferrannini A, et al. Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002;88:331–334.
232. Sanchez Borges M, Capriles-Hulett A, Caballero-Fonseca F, et al. Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol 2001;87: 201–204.
233. Asero R. Intolerance to nonsteroidal anti-inflammatory drugs might precede by years the onset of chronic urticaria. J Allergy Clin Immunol 2003;111:1095–1098.
234. Kemp SF, Lockey RF, Wolf BL, et al. Anaphylaxis. A review of 266 cases. Arch Intern Med 1995;155:1749–1754.
235. Davidson KA, Ringpfeil F, Lee JB. Ibuprofen-induced bullous leukocytoclastic vasculitis. Cutis 2001;67:303–307.
236. De Silva B, Banney L, Uttley W, et al. Pseudoporphyria and nonsteroidal antiinflammatory agents in children with juvenile idiopathic arthritis. Pediatr Dermatol 2000;17:480–483.
237. Cutaneous reactions to analgesic-antipyretics and nonsteroidal anti-inflammatory drugs. Analysis of reports to the spontaneous reporting system of the Gruppo Italiano Studi Epidemiologici in Dermatologia. Dermatology 1993;186:164–169.
238. Moore DE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf 2002;25:345–372.
239. Greenberg GN. Recurrent sulindac-induced aseptic meningitis in a patient tolerant to other nonsteroidal anti-inflammatory drugs. South Med J 1988;81:1463–1464.
240. Marinac JS. Drug- and chemical-induced aseptic meningitis: a review of the literature. Ann Pharmacother 1992;26:813–822.
241. Goodwin SD, Glenny RW. Nonsteroidal anti-inflammatory drug-associated pulmonary infiltrates with eosinophilia. Review of the literature and Food and Drug Administration Adverse Drug Reaction reports. Arch Intern Med 1992;152:1521–1524.
242. Yip L, Dart RC, Gabow PA. Concepts and controversies in salicylate toxicity. Emerg Med Clin North Am 1994;12:351–364.
243. Glasgow JF, Middleton B. Reye syndrome—insights on causation and prognosis. Arch Dis Child 2001;85:351–353.
244. Forsyth BW, Horwitz RI, Acampora D, et al. New epidemiologic evidence confirming that bias does not explain the aspirin/Reye’s syndrome association. JAMA 1989;261:2517–2524.
245. Hall SM. Reye’s syndrome and aspirin: a review. Br J Clin Pract Suppl 1990;70:4–11.
246. Belay ED, Bresee JS, Holman RC, et al. Reye’s syndrome in the United States from 1981 through 1997. N Engl J Med 1999;340: 1377–1382.
247. Roberts LJ 2nd, Morrow JD. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird LE, eds. Pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill, 2001:687–731.
248. Brater DC. Drug-drug and drug-disease interactions with nonsteroidal anti-inflammatory drugs. Am J Med 1986;80:62–77.
249. Watkins J, Abbott EC, Hensby CN, et al. Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin. BMJ 1980;281:702–705.
250. Uwai Y, Saito H, Inui K. Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. Eur J Pharmacol 2000;409:31–36.
251. Kremer JM, Hamilton RA. The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J Rheumatol 1995;22:2072–2077.
252. Tracy TS, Krohn K, Jones DR, et al. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol 1992;42: 121–125.
253. Iqbal MP, Baig JA, Ali AA, et al. The effects of non-steroidal anti-inflammatory drugs on the disposition of methotrexate in patients with rheumatoid arthritis. Biopharm Drug Dispos 1998;19:163–167.
254. Verbeeck RK. Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 1990;19:44–66.
255. Ragheb M. The clinical significance of lithium-nonsteroidal anti-inflammatory drug interactions. J Clin Psychopharmacol 1990;10: 350–354.
256. Graham DY, Malaty HM. Alendronate and naproxen are synergistic for development of gastric ulcers. Arch Intern Med 2001;161: 107–110.
257. Kovarik JM, Mueller EA, Gerbeau C, et al. Cyclosporine and nonsteroidal antiinflammatory drugs: exploring potential drug interactions and their implications for the treatment of rheumatoid arthritis. J Clin Pharmacol 1997;37:336–343.
258. Tugwell P, Ludwin D, Gent M, et al. Interaction between cyclosporin A and nonsteroidal antiinflammatory drugs. J Rheumatol 1997;24: 1122–1125.
259. Davies NM, McLachlan AJ, Day RO, et al. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000;38:225–242.
260. Klose TS, Ibeanu GC, Ghanayem BI, et al. Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen. Arch Biochem Biophys 1998; 357:240–248.
261. Yamazaki H, Inoue K, Chiba K, et al. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol 1998;56:243–251.
262. Chesne C, Guyomard C, Guillouzo A, et al. Metabolism of meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica 1998;28:1–13.
263. Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996;39:723–731.
264. Hollingworth P. The use of non-steroidal anti-inflammatory drugs in paediatric rheumatic diseases. Br J Rheumatol 1993;32:73–77.
265. Berde CB, Sethna NF. Analgesics for the treatment of pain in children. N Engl J Med 2002;347:1094–1103.
266. Olkkola KT, Maunuksela EL. The pharmacokinetics of postoperative intravenous ketorolac tromethamine in children. Br J Clin Pharmacol 1991;31:182–184.
267. Cuzzolin L, Dal Cere M, Fanos V. NSAID-induced nephrotoxicity from the fetus to the child. Drug Saf 2001;24:9–18.
268. Pickering AE, Bridge HS, Nolan J, et al. Double-blind, placebo-controlled analgesic study of ibuprofen or rofecoxib in combination with paracetamol for tonsillectomy in children. Br J Anaesth 2002; 88:72–77.
269. Stempak D, Gammon J, Klein J, et al. Single-dose and steady-state pharmacokinetics of celecoxib in children. Clin Pharmacol Ther 2002;72:490–497.
270. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2002.
271. Werler MM, Mitchell AA, Shapiro S. The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med 1989;321:1639–1642.
272. Collins E, Turner G. Letter: Salicylates and pregnancy. Lancet 1973; 2:1494.
273. Niebyl JR. Drugs in pregnancy and lactation. In: Gabbe SG, Niebyl JR, Simpson JL, eds. Obstetrics: normal and problem pregnancies, 4th ed. New York: Churchill Livingstone, 2002:221–50.
274. Laine L. Gastrointestinal safety of coxibs and outcomes studies: what’s the verdict? J Pain Symptom Manage 2002;23(suppl):5–10; discussion 11–14.
275. Holm L, Phillipson M, Perry MA. NO-flurbiprofen maintains duodenal blood flow, enhances mucus secretion contributing to lower mucosal injury. Am J Physiol Gastrointest Liver Physiol 2002;283: G1090–G1097.
276. Wallace JL, Reuter B, Cicala C, et al. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 1994;107:173–179.